Kumudini Nadella, Uma Addepally, Naushad Shaik Mohammad, Mridula Rukmini, Borgohain Rupam, Kutala Vijay Kumar
Centre for Biotechnology, Jawaharlal Nehru Technological University, Hyderabad, India.
School of Chemical & Biotechnology, SASTRA University, Thanjavur, India.
Neurosci Lett. 2014 May 7;568:1-5. doi: 10.1016/j.neulet.2014.03.044. Epub 2014 Mar 28.
This study from South India was performed to ascertain the impact of seven functional polymorphisms of one-carbon metabolic pathway on total plasma homocysteine levels and susceptibility to PD. A total of 151 cases of Parkinson's disease and 416 healthy controls were analyzed for fasting plasma homocysteine levels by reverse phase HPLC. PCR-RFLP approaches were used to analyze glutamate carboxypeptidase II (GCPII) 1561 C>T, reduced folate carrier 1 (RFC1) 80 G>A, cytosolic serine hydroxymethyl transferase (cSHMT) 1420 C>T, methylene tetrahydrofolate reductase (MTHFR) 677 C>T, methionine synthase (MTR) 2756 A>G and methionine synthase reductase (MTRR) 66 A>G polymorphisms. PCR-AFLP was used for the analysis of thymidylate synthase (TYMS) 5'-UTR 28bp tandem repeat. PD cases exhibited elevated plasma homocysteine levels compared to controls (men: 28.8 ± 6.9 vs. 16.4 ± 8.8 μmol/L; women: 25.4 ± 5.3 vs. 11.2 ± 5.1μmol/L). Homocysteine levels showed positive correlation with male gender (r=0.39, p<0.0001) and MTRR 66 A>G (r=0.31, p<0.0001) whereas an inverse correlation was observed with cSHMT 1420 C>T polymorphism. MTRR 66 A>G polymorphism showed independent risk for PD (OR: 3.42, 95% CI: 2.35-4.98) whereas cSHMT 1420 C>T conferred protection against PD (OR: 0.11, 95% CI: 0.07-0.17). Multifactor dimensionality reduction analysis showed synergistic interactions between MTHFR 677 C>T and MTRR 66 A>G, whereas cSHMT 1420 C>T exhibited counteracting interactions in altering susceptibility to PD. To conclude, PD cases exhibited hyperhomocysteinemia and MTRR 66 A>G and cSHMT 1420 C>T gene variants were shown to modulate PD risk by altering the homocysteine levels.
这项来自印度南部的研究旨在确定一碳代谢途径的七个功能多态性对血浆总同型半胱氨酸水平及帕金森病易感性的影响。通过反相高效液相色谱法对151例帕金森病患者和416名健康对照者的空腹血浆同型半胱氨酸水平进行了分析。采用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)方法分析了谷氨酸羧肽酶II(GCPII)1561 C>T、还原型叶酸载体1(RFC1)80 G>A、胞质丝氨酸羟甲基转移酶(cSHMT)1420 C>T、亚甲基四氢叶酸还原酶(MTHFR)677 C>T、甲硫氨酸合成酶(MTR)2756 A>G和甲硫氨酸合成酶还原酶(MTRR)66 A>G多态性。采用聚合酶链反应-扩增片段长度多态性(PCR-AFLP)分析胸苷酸合成酶(TYMS)5'-UTR 28bp串联重复序列。与对照组相比,帕金森病患者血浆同型半胱氨酸水平升高(男性:28.8±6.9 vs. 16.4±8.8 μmol/L;女性:25.4±5.3 vs. 11.2±5.1μmol/L)。同型半胱氨酸水平与男性性别呈正相关(r=0.39,p<0.0001)以及与MTRR 66 A>G呈正相关(r=0.31,p<0.0001),而与cSHMT 1420 C>T多态性呈负相关。MTRR 66 A>G多态性显示为帕金森病的独立危险因素(比值比:3.42,95%可信区间:2.35-4.98),而cSHMT 1420 C>T对帕金森病具有保护作用(比值比:0.11,95%可信区间:0.07-0.17)。多因素降维分析显示MTHFR 677 C>T和MTRR 66 A>G之间存在协同相互作用,而cSHMT 1420 C>T在改变帕金森病易感性方面表现出拮抗相互作用。总之,帕金森病患者表现为高同型半胱氨酸血症,并且MTRR 66 A>G和cSHMT 1420 C>T基因变异通过改变同型半胱氨酸水平来调节帕金森病风险。